Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOVODAK added to hydroxychloroquine-based outpatient treatment for COVID-19
IRCT20200403046926N1Phase 3Completed
- Sponsor
- Mazandaran University of Medical Sciences
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of sofosbuvir + daclatasvir and hydroxychloroquine in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Mazandaran University of Medical Sciences. Primary endpoints: Symptoms ending, Lymphopenic condition and 2 more. Started Apr 2020; status: completed.
02
Drugs
sofosbuvir + daclatasvirhydroxychloroquine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on IRCT20200403046926N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200403046926N1.